Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours

Next Previous
Trial Profile

A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 225 Actinium FPI 1434 (Primary) ; FPI-1175 (Primary) ; FPI-1547 (Primary)
  • Indications Adrenocortical carcinoma; Advanced breast cancer; Cervical cancer; Endometrial cancer; Ewing's sarcoma; Head and neck cancer; HER2 negative breast cancer; Ovarian cancer; Solid tumours; Squamous cell cancer; Uveal melanoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Fusion Pharmaceuticals

    • Most Recent Events

    • 04 Jan 2024 Results presented in a Fusion Pharmaceuticals media release.
    • 04 Jan 2024 According to a Fusion Pharmaceuticals media release, the company plans to complete and further evaluate results from Cohort 2 and hold a Safety Review Committee (SRC) meeting to evaluate the emerging data and plans to share more details on the data and the FPI-1434 development program in mid-2024.
    • 07 Nov 2023 According to a Fusion Pharmaceuticals media release, company is currently enrolling Cohort 2 in the cold/hot dosing regimen at 25 kBq/kg and is on track to share data from the second cohort in this Phase 1 study of FPI-1434 in patients with solid tumors expressing IGF-1R around the end of this year.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top